A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. - Wikidata - wikimedia - TriplyDB

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.

http://www.wikidata.org/entity/Q40522944

about

Immune checkpoint inhibitors: therapeutic advances in melanoma Rad52 deficiency decreases development of lung squamous cell carcinomas by enhancing immuno-surveillance.Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters.Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant.Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options Bispecific antibodies in cancer immunotherapy Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

P2860

Q26775591-8CF39DAC-AE70-41F3-9D2A-9C04FDC71F88 Q33798257-8A1523DE-8803-49A7-A47B-81B323D4A72A Q33805073-265E4F00-3840-453A-8A03-BB61951D67EC Q36255636-57AE6162-4CE3-4B04-929D-E2A2645C8B09 Q38786054-D961A693-10AB-4237-8F95-B9EEA121365A Q39043844-1B3381C0-1FA3-4B7A-894F-0BE783017E54 Q47325431-D2E67567-7A31-489A-8451-24A66D7EE683 Q56890107-AB85AED3-AA9C-468D-92F8-86E99E88B75C Q56893015-FDB9D3B8-8BC1-45E6-9358-FBBA0548D835 Q57132855-602D9DF7-B0AD-4505-AC7A-11105EFAD6AF

P2860

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.

http://www.wikidata.org/entity/Q40522944

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A phase 1b clinical trial of t ...... alignant pleural mesothelioma.

@en

type

label

A phase 1b clinical trial of t ...... alignant pleural mesothelioma.

@en

prefLabel

A phase 1b clinical trial of t ...... alignant pleural mesothelioma.

@en

P1433

Q40522944-DE665C9B-80F3-43C9-A9E4-2D190BD75048

P1476

Q40522944-C8C72E81-6C50-4F4E-A204-9035E946B2AB

P2093

Q40522944-07534116-E7E2-4FE7-84C3-D35586FFA8B3

Q40522944-0E3D1637-625B-4221-9731-C9C2BBBB9CF1

Q40522944-20AF60A0-226E-4DFF-B56B-4A76CE9A203A

Q40522944-5C052E9D-CE7E-4376-A523-CA94220464C6

Q40522944-75488DD3-AAB3-4CFD-9E62-DB4E62AF5FFF

Q40522944-9126FD78-3145-4586-8EBE-E09C8156C6CA

Q40522944-C817940A-1F7B-4B91-BAFF-3277A317FE42

Q40522944-EA1CFDF4-BAAC-485A-8406-E719EE7CC4D6

P2860

Q40522944-0F7F03F0-8C8A-42B7-8EBC-C7ADBCF2622C

Q40522944-20B2DCE4-8002-42D4-9A9C-F9375066A3D3

Q40522944-25156306-98C4-47C9-BF50-4852BF3E30CE

Q40522944-2AC4FEBC-4891-403E-B90C-F93C3FEE00D0

Q40522944-604CC590-BAEE-43B8-801C-7EACD1BD871F

Q40522944-8692CDF6-509E-49DF-B1DC-EF50FBD7750D

Q40522944-8FC2D37D-2BD7-4EBE-8F3E-28607343B714

Q40522944-B6FE6689-7426-40AD-9B33-6E7A9E81E5B3

Q40522944-BFC7F803-2E77-43C6-9D49-BA0E5B61A678

Q40522944-E340436A-77B1-42D7-8A9C-EC6AFFA556F2

P304

Q40522944-1C22E6B3-A42F-45FA-9318-DCFFAE217112

P31

Q40522944-D00D96EA-373F-45C4-A826-4A8633120D4B

P356

Q40522944-11D37BB4-E975-4D94-B571-1E77C25E3B9D

P433

Q40522944-87EC69FC-2C0D-4988-AFEA-C74C97236111

P478

Q40522944-F6B77202-DD51-4221-8B27-CAA2931E0025

P50

Q40522944-472AD1E7-B0E7-42E2-A814-9377AD257EB5

Q40522944-64E93BAF-2A0C-4F25-A74A-4D29E184FF4B

Q40522944-716356F4-76AE-45E7-A26C-448A8B39CF5B

Q40522944-A5FE5249-5FD5-4532-9269-E1D69DFA264B

Q40522944-A85A5E84-B8B2-4A68-81C6-1C45B23B4300

P577

Q40522944-B66B2B1B-B002-485B-A72E-90A441AE6BF2

P698

Q40522944-05E2D7AC-FA2D-43AE-883D-5DA4CAE12C54

P356

P1433

Annals of Oncology

P1476

A phase 1b clinical trial of t ...... malignant pleural mesothelioma

@en

P2093

A Hasani

http://www.w3.org/2001/XMLSchema#string

A Segal

http://www.w3.org/2001/XMLSchema#string

A W Musk

http://www.w3.org/2001/XMLSchema#string

B W S Robinson

http://www.w3.org/2001/XMLSchema#string

J Creaney

http://www.w3.org/2001/XMLSchema#string

M J McCoy

http://www.w3.org/2001/XMLSchema#string

M J Millward

http://www.w3.org/2001/XMLSchema#string

R A Lake

http://www.w3.org/2001/XMLSchema#string

P2860

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

B cells as antigen presenting cells.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

B-cell biology and development.

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.

Prospect of targeting the CD40 pathway for cancer therapy.

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

P304

2483-2490

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDV387

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Berwin A. Turlach

Roslyn J Francis

Alistair M Cook

Alison M McDonnell

P577

2015-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26386124

http://www.w3.org/2001/XMLSchema#string